These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 11751522)

  • 1. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
    Motwani M; Jung C; Sirotnak FM; She Y; Shah MA; Gonen M; Schwartz GK
    Clin Cancer Res; 2001 Dec; 7(12):4209-19. PubMed ID: 11751522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells.
    Motwani M; Sirotnak FM; She Y; Commes T; Schwartz GK
    Cancer Res; 2002 Jul; 62(14):3950-5. PubMed ID: 12124325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
    Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
    Ambrosini G; Seelman SL; Qin LX; Schwartz GK
    Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
    Darpolor MM; Kennealey PT; Le HC; Zakian KL; Ackerstaff E; Rizwan A; Chen JH; Sambol EB; Schwartz GK; Singer S; Koutcher JA
    NMR Biomed; 2011 Nov; 24(9):1159-68. PubMed ID: 21994185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
    Guo J; Zhou AW; Fu YC; Verma UN; Tripathy D; Frenkel EP; Becerra CR
    Acta Pharmacol Sin; 2006 Oct; 27(10):1375-81. PubMed ID: 17007746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
    Xiang H; Fox JA; Totpal K; Aikawa M; Dupree K; Sinicropi D; Lowe J; Escandón E
    Oncogene; 2002 May; 21(22):3611-9. PubMed ID: 12032863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
    Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
    Whitacre CM; Zborowska E; Willson JK; Berger NA
    Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin.
    Han Z; Wei W; Dunaway S; Darnowski JW; Calabresi P; Sedivy J; Hendrickson EA; Balan KV; Pantazis P; Wyche JH
    J Biol Chem; 2002 May; 277(19):17154-60. PubMed ID: 11877436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Tse AN; Schwartz GK
    Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
    Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
    Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
    LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
    Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
    Shapiro GI
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.